Jefferson University Hospitals

Physician Profile

Russell Schilder, MD

Jefferson University Physician

Academic Title: Professor
Medical Oncology Director, Gynecologic Oncology Program

Specialties
Medical Oncology
Medical Oncology - Gynecologic Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 320A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 503-7697
Abington
1200 Old York Road
1 Widener - AMH
Abington PA 19001
Phone: (215) 885-0220
Fax: (215) 876-0740

Medical Services

Board Certifications

  • Medical Oncology
  • Hematology
  • Internal Medicine

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2016,2015,2014,2013,2012

Notes

Dr. Schilder specializes in Cervical, Endometrial, Ovarian and Uterine Cancer.

Education

  • University of Miami School of Medicine, Medical School

Internship

  • Temple University Hospital

Residency

  • Temple University Hospital

Fellowship

  • Temple University Hospital

Recent Publications

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Ovarian Cancer: New Targets and Future Directions

A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study

Hereditary ovarian cancer: Not only BRCA 1 and 2 Genes

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion

Refractory fallopian tube carcinoma - Current perspectives in pathogenesis and management

Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer

Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study

Influence of bevacizumab on vaginal cuff evisceration eight months after ovarian cancer cytoreduction surgery: A case report

A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study

Epithelial-to-mesenchymal transition and cellular membrane receptors in ovarian cancer: Moving forward in the era of molecularly targeted therapy

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary

A Phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix

Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions